17 Scopus citations


mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/ phenotypes beyond genes in kidney cancer, like a braided river.

Original languageEnglish
Pages (from-to)2320-2322
Number of pages3
JournalClinical Cancer Research
Issue number10
StatePublished - May 15 2016


Dive into the research topics of 'Therapeutic guide for mTOuRing through the braided kidney cancer genomic river'. Together they form a unique fingerprint.

Cite this